
    
      Primary Outcome Measure: Progression free survival of apatinib in RAIR-DTC.

      Secondary Outcome Measures: Disease control rate, objective response rate, duration of
      response, changes of Tg and TgAb level in serum, overall survival, side effects and quality
      of life.
    
  